Latest Period
Q4 2025
Security Snapshot
Celldex Therapeutics, Inc. - Common Stock (CLDX) Institutional Ownership
CUSIP: 15117B202
13F Institutional Holders and Ownership History from Q4 2018 to Q1 2026
Institutions Reporting
183
Shares (Excl. Options)
73,373,402
Price
$27.16
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- CLDX on Nasdaq
- Shares outstanding
- 66,669,149
- Price per share
- $31.26
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 73,373,402
- Total reported value
- $1,992,599,502
- % of total 13F portfolios
- 0%
- Share change
- +1,651,612
- Value change
- +$45,987,039
- Number of holders
- 183
- Price from insider filings
- $31.26
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- CLDX - Celldex Therapeutics, Inc. - Common Stock is tracked under CUSIP 15117B202.
- 183 institutions reported positions in Q4 2025.
- 11 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 183 to 48 between Q4 2025 and Q1 2026.
- Reported value moved from $1,992,599,502 to $128,303,870.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 183 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 15117B202?
CUSIP 15117B202 identifies CLDX - Celldex Therapeutics, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 15117B202:
Significant Owners of Celldex Therapeutics, Inc. - Common Stock (CLDX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP | 12% | +10% | $219,442,153 | +$18,600,852 | 8,079,608 | +9.3% | Wellington Management Group LLP | 31 Dec 2025 |
| Kynam Capital Management, LP | 9.8% | +27% | $136,045,000 | +$30,051,147 | 6,500,000 | +28% | Kynam Capital Management, LP | 31 Mar 2025 |
| FMR LLC | 7.3% | $101,670,991 | 4,857,668 | FMR LLC | 31 Dec 2024 | |||
| BlackRock, Inc. | 7.3% | -12% | $100,867,802 | -$13,842,621 | 4,819,293 | -12% | BlackRock, Inc. | 31 Mar 2025 |
| Bellevue Group AG | 5.4% | $93,589,097 | 3,617,669 | Bellevue Group AG | 18 Aug 2025 | |||
| VANGUARD CAPITAL MANAGEMENT LLC | 5.2% | $109,332,337 | 3,446,795 | Vanguard Capital Management | 31 Mar 2026 | |||
| STATE STREET CORP | 5.1% | $92,281,885 | 3,397,713 | STATE STREET CORPORATION | 31 Dec 2025 | |||
| Commodore Capital LP | 4.6% | -8% | $78,343,026 | -$8,321,474 | 3,028,335 | -9.6% | Commodore Capital LP | 30 Sep 2025 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.6% | -36% | $61,640,475 | -$30,382,633 | 2,382,701 | -33% | T. Rowe Price Associates, Inc. | 30 Sep 2025 |
| Point72 Asset Management, L.P. | 2.6% | -59% | $43,255,582 | -$66,568,658 | 1,758,357 | -61% | Point72 Asset Management, L.P. | 31 Dec 2025 |
| EVENTIDE ASSET MANAGEMENT, LLC | 2% | $30,459,938 | 1,356,186 | Eventide Asset Management, LLC | 30 Jun 2025 |
As of 31 Dec 2025, 183 institutional investors reported holding 73,373,402 shares of Celldex Therapeutics, Inc. - Common Stock (CLDX). This represents 110% of the company’s total 66,669,149 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Celldex Therapeutics, Inc. - Common Stock (CLDX) together control 90% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP | 12% | 8,079,608 | +39% | 0.04% | $219,442,154 |
| Kynam Capital Management, LP | 8.9% | 5,943,180 | -2.6% | 11% | $161,416,769 |
| BlackRock, Inc. | 8.2% | 5,451,815 | -0.98% | 0% | $148,071,294 |
| FMR LLC | 7.4% | 4,907,469 | -1.1% | 0.01% | $133,286,863 |
| VANGUARD GROUP INC | 6% | 4,027,407 | +1.8% | 0% | $109,384,374 |
| Bellevue Group AG | 5.4% | 3,617,669 | +1.7% | 1.9% | $98,255,890 |
| STATE STREET CORP | 5.1% | 3,397,713 | +20% | 0% | $92,281,885 |
| Commodore Capital LP | 3.8% | 2,565,000 | -15% | 4.6% | $69,665,400 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.1% | 2,039,705 | -14% | 0.01% | $55,399,000 |
| Deep Track Capital, LP | 2.9% | 1,900,738 | -5% | 1.2% | $51,624,044 |
| BRAIDWELL LP | 2.8% | 1,858,109 | +214% | 1.6% | $50,466,240 |
| Point72 Asset Management, L.P. | 2.6% | 1,758,357 | -55% | 0.07% | $47,756,976 |
| EVENTIDE ASSET MANAGEMENT, LLC | 2.5% | 1,642,559 | -12% | 0.7% | $44,607,415 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.4% | 1,627,529 | -1.2% | 0% | $44,211,330 |
| Eversept Partners, LP | 2.2% | 1,434,725 | +24% | 2.2% | $38,967,131 |
| MILLENNIUM MANAGEMENT LLC | 1.8% | 1,212,705 | +24% | 0.02% | $32,937,068 |
| NOVO HOLDINGS A/S | 1.8% | 1,200,000 | 0% | 2.5% | $32,592,000 |
| Vestal Point Capital, LP | 1.7% | 1,165,000 | -3.3% | 1.2% | $31,641,400 |
| GOLDMAN SACHS GROUP INC | 1.6% | 1,068,131 | +3.8% | 0% | $29,010,438 |
| Polar Capital Holdings Plc | 1.5% | 1,008,163 | -22% | 0.13% | $27,381,707 |
| Pictet Asset Management Holding SA | 1.5% | 968,616 | -20% | 0.03% | $26,307,611 |
| Fisher Asset Management, LLC | 1.4% | 937,158 | +1.1% | 0.01% | $25,453,210 |
| Elmind Capital, LP | 1.3% | 865,000 | 0% | 6.9% | $23,493,400 |
| AMERICAN CENTURY COMPANIES INC | 1.3% | 855,226 | +4.9% | 0.01% | $23,227,976 |
| Rock Springs Capital Management LP | 1% | 692,538 | -4% | 0.97% | $18,809,332 |
Institutional Holders of Celldex Therapeutics, Inc. - Common Stock (CLDX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 4,044,496 | $128,303,870 | +$13,401,531 | $31.72 | 48 |
| 2025 Q4 | 73,373,402 | $1,992,599,502 | +$45,987,039 | $27.16 | 183 |
| 2025 Q3 | 70,729,708 | $1,829,814,017 | -$41,022,042 | $25.87 | 180 |
| 2025 Q2 | 72,686,329 | $1,479,214,886 | -$18,971,957 | $20.35 | 178 |
| 2025 Q1 | 73,628,376 | $1,336,550,222 | -$25,518,368 | $18.15 | 170 |
| 2024 Q4 | 73,686,767 | $1,861,792,917 | -$10,935,353 | $25.27 | 172 |
| 2024 Q3 | 71,809,989 | $2,440,639,326 | +$62,002,971 | $33.99 | 174 |
| 2024 Q2 | 69,594,154 | $2,575,716,559 | +$1,332,092 | $37.01 | 181 |
| 2024 Q1 | 69,311,318 | $2,908,781,828 | +$362,625,073 | $41.97 | 196 |
| 2023 Q4 | 60,989,057 | $2,418,831,729 | +$410,573,840 | $39.66 | 162 |
| 2023 Q3 | 50,572,705 | $1,391,763,899 | +$5,531,719 | $27.52 | 140 |
| 2023 Q2 | 50,188,683 | $1,702,972,802 | +$19,493,416 | $33.93 | 148 |
| 2023 Q1 | 49,503,692 | $1,779,547,358 | +$24,122,749 | $35.98 | 158 |
| 2022 Q4 | 48,677,430 | $2,169,609,749 | -$9,316,822 | $44.57 | 163 |
| 2022 Q3 | 49,338,461 | $1,386,923,833 | +$32,333,656 | $28.11 | 146 |
| 2022 Q2 | 48,218,738 | $1,300,004,065 | -$45,672,202 | $26.96 | 146 |
| 2022 Q1 | 49,602,527 | $1,689,417,077 | +$106,143,717 | $34.06 | 157 |
| 2021 Q4 | 46,338,765 | $1,790,195,856 | +$97,400,922 | $38.64 | 170 |
| 2021 Q3 | 43,227,306 | $2,333,703,184 | +$430,296,249 | $53.99 | 156 |
| 2021 Q2 | 35,559,554 | $1,189,106,240 | +$60,325,552 | $33.44 | 127 |
| 2021 Q1 | 34,503,199 | $709,497,850 | -$40,255,166 | $20.60 | 109 |
| 2020 Q4 | 36,816,222 | $645,045,236 | +$72,177,637 | $17.52 | 120 |
| 2020 Q3 | 32,156,087 | $476,873,776 | +$67,764,471 | $14.83 | 82 |
| 2020 Q2 | 27,786,246 | $361,216,517 | +$310,785,532 | $13.00 | 63 |
| 2020 Q1 | 3,949,694 | $6,557,892 | +$7,227 | $1.66 | 32 |
| 2019 Q4 | 3,904,189 | $8,706,543 | +$447,617 | $2.23 | 34 |
| 2019 Q3 | 3,708,146 | $7,895,004 | +$465,004 | $2.13 | 40 |
| 2019 Q2 | 3,466,005 | $9,286,115 | +$2,108,302 | $2.68 | 39 |
| 2019 Q1 | 2,603,854 | $12,809,043 | +$12,313,782 | $4.92 | 39 |
| 2018 Q4 | 100,357 | $20,000 | +$20,000 | $0.20 | 1 |